• RenovoRx forecasts 2026 revenue of $3.75 million to $4.25 million.
• Third-quarter revenue reached $1.07 million, more than quadrupling year over year.
• Nine-month revenue rose 138% to $2.5 million.
• At least 36 active commercial cancer centers are targeted by year-end, versus 26 as of November 5, 2026.
• Cash reserves are expected to fund operations into the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.